A finalized mandatory model will test whether tying Medicare Part B drug rebates to international prices can lower costs for ...
Rotterdam-based diagnosis (2 of oligo/anovulation, hyperandrogenism, polycystic ovarian morphology) persists, but ...
Weekly survodutide 3.6 mg/6.0 mg achieved up to 13.1% mean weight loss at week 76 versus 3.1% with placebo, meeting ...
LIBERTY met all primary/secondary endpoints, with lower 6-day TEAEs/ISRs/hypersensitivity (56.5% vs 91.4%) and systemic AEs ...
Lung cancer screening eligibility increased markedly from 2018–2023 under USPSTF criteria, reflecting aging and substantial ...
Sean Wharton, MD, PharmD, discusses new data on survodutide from the phase 3 SYNCHRONIZE-2 trial. Survodutide (Boehringer Ingelheim), a dual glucagon-like peptide-1 (GLP-1) and glucagon receptor ...
Diagnosed atopic dermatitis (AD) affected about 6.9 million insured people in the US in 2023, but roughly half of them filled ...
In "Closing Reflections on the Future of Vitiligo Care," each panelist shares closing reflections on where vitiligo care is ...
Dr. Chung asks what operational changes practices should prioritize to prepare for an expanding hepatitis B treatment ...
Population Health, Equity & Outcomes is a quarterly publication dedicated to providing a platform for the exchange of research, policy analysis, and insights that aim to improve health outcomes and ...
FDA expanded mavacamten’s indication to include pediatric patients ≥66 lb with symptomatic oHCM, positioning it as the only FDA-approved oHCM therapy for children and adolescents. SCOUT-HCM randomized ...
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results